Impact of PlA polymorphism of platelet GP IIb/IIIa receptors on clinical course during long-term LVAD support is independent of type of LVAD.
Potapov
Evgenij V
EV
Hetzer
Roland
R
D000925:Anticoagulants / Q000627:therapeutic use; D016824:Antigens, Human Platelet / Q000235:genetics*; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D004867:Equipment Design; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006353:Heart-Assist Devices / Q000145:classification; D006474:Hemorrhagic Disorders / Q000209:etiology / Q000235:genetics; D006801:Humans; D015994:Incidence; D039661:Integrin beta3; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000235:genetics*; D011110:Polymorphism, Genetic; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D019851:Thrombophilia / Q000209:etiology / Q000235:genetics; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D016824:Antigens, Human Platelet; C061248:ITGB3 protein, human; D039661:Integrin beta3; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin